Strides Arcolab receives ANDA approval for Efavirenz tablet

3805 Investors following Strides Arcolab. Share this News with them.

0

Like this story, share it with millions of investors on M3

Strides Arcolab receives ANDA approval for Efavirenz tablet

Strides Arcolab receives ANDA approval from US-FDA for Efavirenz tablets

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Strides Arcolab receives 2 NDA approvals from US-FDA JV of Strides Arcolab & Invent Farma acquires Farma Plus Strides Arcolab FY06 global revenues grows 43% to Rs 760cr ALSO READ See latest News about Strides Arcolab See previous management interviews See what other Experts & Brokerages are saying about Strides Arcolab Strides Arcolab BSE | NSE 25/05/12 Are Mutual Funds betting on Strides Arcolab?

Strides Arcolab today announced that it has received tentative approval from the United States - Food and Drug Administration for Efavirenz tablets under the expedited review provisions of the President's Emergency Plan for Aids Relief [PEPFAR] program. 

Efavirenz, the generic version of Bristol Myers Squibb's SUSTIVA, is a non nucleoside reverse transcriptase inhibitor which prevents the AIDS virus from reproducing in cells. Efavirenz is used in combination with other anti-retroviral agents for the treatment of HIV-infections and is a key component of drug regimens for patients who are on concurrent treatment for tuberculosis.

Arun Kumar - Vice Chairman and Managing Director, Strides Arcolab said "We now have ANDA/ NDA approvals for all first line anti-retroviral drugs. This will give a major boost to our AIDS, TB and Malaria [ATM] initiative particularly in Africa and South Asian countries."

The company also partners the Clinton Foundation to ensure availability of affordable quality generic ARVs in least developed countries.

Sourced From: Adfactors Public Relations Pvt Ltd